Disc Medicine, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Investors learn how the company performed financially in the second quarter and what management expects ahead.
The company secured $30 million in immediate funds and extended access to future borrowing, improving financial runway.
Shareholders chose the board members who oversee the company's direction and CEO performance.
Investors learn how the company performed financially in the first quarter and strategic updates from leadership.
A major setback in drug development forced cost cuts, affecting shareholder value and company direction.
Stocky reads Disc Medicine, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Disc Medicine, Inc.'s most recent tracked filing was a 10-Q on 30 Jul 2026: Q2 2026 financial results announced July 30.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.